Portrazza (necitumumab)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- necitumumab
- Company
- Eli Lilly Nederland B.V.
- Status
- Withdrawn
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- EU approval
- Mon 15 Feb 2016
- Designations
- Additional monitoring
- Application
- EMEA/H/C/003886
- ATC
- L01
- Official record
- www.ema.europa.eu
Indication
Portrazza in combination with gemcitabine and cisplatin chemotherapy is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.
Regulatory milestones
No milestones recorded in the last year.
Follow Portrazza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.